Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesNon-Current ReceivablesOther Gross PP&E AdjustmentsReceivables - NetReceivables Refunds
Ratios

Sangamo Therapeutics (SGMO) Accumulated Depreciation & Amortization (2016 - 2024)

Sangamo Therapeutics (SGMO) has 14 years of Accumulated Depreciation & Amortization data on record, last reported at $5.1 million in Q4 2024.

  • For Q4 2024, Accumulated Depreciation & Amortization fell 66.1% year-over-year to $5.1 million; the TTM value through Dec 2024 reached $5.1 million, down 66.1%, while the annual FY2024 figure was $5.1 million, 66.1% down from the prior year.
  • Accumulated Depreciation & Amortization reached $5.1 million in Q4 2024 per SGMO's latest filing, down from $15.1 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $15.1 million in Q4 2023 and bottomed at $5.1 million in Q4 2024.
  • Average Accumulated Depreciation & Amortization over 5 years is $9.5 million, with a median of $9.4 million recorded in 2021.
  • Peak YoY movement for Accumulated Depreciation & Amortization: skyrocketed 65.6% in 2021, then crashed 66.1% in 2024.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $5.7 million in 2020, then soared by 65.6% to $9.4 million in 2021, then increased by 28.28% to $12.1 million in 2022, then increased by 24.42% to $15.1 million in 2023, then plummeted by 66.1% to $5.1 million in 2024.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $5.1 million in Q4 2024, $15.1 million in Q4 2023, and $12.1 million in Q4 2022.